S4 Medical

What S4 Medical does

S4 Medical Corp is a privately held medical device company founded in 2017 in Chagrin Falls, Ohio by Bill Fuller and Dr. Emile Daoud. The company develops and commercializes the esolution® device, a single-use, FDA-cleared (2023) and 510(k)-cleared (late 2024) esophageal protection system used during catheter ablation procedures for atrial fibrillation. The device employs vacuum suction and mechanical deflection to deviate the esophagus left or right, reducing the risk of thermal injury, which has been reported in up to 47% of AF ablation patients. It is compatible with any ablation energy source and mapping system, works with 9Fr temperature probes, and requires no proprietary hardware or software.

The company's revenue model is based on direct hardware sales of the esolution consumable to hospitals and cardiac centers with electrophysiology programs. It also pursues federal healthcare sales through a January 2026 channel partnership with Lovell Government Services, leveraging SDVOSB status to access VA, DoD, and Indian Health Service facilities via Federal Supply Schedule, GSA Advantage, DLA ECAT, and DoD DAPA contract vehicles. Marketing is primarily driven through peer-reviewed publications (notably the EASY AF trial in JACC: Electrophysiology), medical conference presentations, and direct enterprise field sales.

As of the latest data, S4 Medical operates with 1-10 employees and has raised approximately $11.6 million cumulatively across multiple funding rounds (including a $5M round in July 2023). Its primary commercial targets are electrophysiology hospitals and federal healthcare systems performing the 300,000+ annual AF ablation procedures in the United States. The company faces key execution risks including single-product concentration, limited commercial-stage capital relative to typical med-device scaling needs, and a small field-sales footprint relative to large EP competitors.

Name

S4 Medical

Legal name

S4 Medical Corp

Website

https://s4medical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

S4 Medical is a privately held medical device company that develops the FDA-cleared esolution® esophageal protection device, which uses vacuum suction and mechanical deflection to reduce thermal injury during atrial fibrillation ablation. It sells to electrophysiology hospitals and federal healthcare systems in the United States.

Ownership category

akta.pro rank

Product category

Cardiac Electrophysiology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

Keywords

• Cardiac ablation devices
• Esophageal protection devices
• Atrial fibrillation treatment
• Electrophysiology medical devices
• Catheter ablation accessories

Headquarters

HQ city

Broadview Heights

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Device Sales: S4 Medical generates revenue through the sale of its esolution esophageal protection device to hospitals and healthcare systems performing atrial fibrillation ablation procedures. The device is sold as a procedural consumable used during ablation treatments.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

S4 Medical develops and sells the esolution® esophageal protection device, an FDA-cleared medical device that uses vacuum suction and mechanical deflection to deviate the esophagus during atrial fibrillation catheter ablation procedures. The device is sold as a procedural consumable to hospitals, cardiac centers, and federal healthcare systems performing AF ablation, with the goal of reducing thermal injury to the esophagus that has been reported in up to 47% of AF ablation patients.

Product overview

S4 Medical offers a single core product, the esolution® esophageal protection device. This FDA-cleared medical device is specifically designed for use during atrial fibrillation ablation procedures to deviate the esophagus away from ablation energy, reducing the risk of thermal injury. The product works with any ablation energy source and mapping system, requiring no unique hardware, software, or accessories.

Differentiator

Problem solved

Functional benefit

Products and services

• esolution® Esophageal Protection Device The esolution® device is an FDA-cleared esophageal protection system that uses vacuum suction and mechanical deflection to deviate the esophagus during catheter ablation procedures for atrial fibrillation. It provides bilateral deviation to accommodate each patient's pulmonary vein anatomy and any lesion strategy, is compatible with any ablation modality and mapping system, requires no unique hardware or software, and works with 9Fr temperature probes. The device is sold to hospitals, cardiac centers, and federal healthcare systems performing AF ablation procedures.

Quantifiable outcome

• 84% reduction in thermal injury
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Lovell Government ServicescoreChannel Partner/ Reseller/ Distributor · 12 January 2026S4 Medical Corp partnered with Lovell Government Services to expand access to the esolution esophageal protection device across federal healthcare systems including the Veterans Health Administration, Military Health System, and Indian Health Service. Lovell serves as S4 Medical's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor and will add the products to Federal Supply Schedule, GSA Advantage, DLA ECAT, and DoD DAPA contract vehicles within 30-60 days of the agreement.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Biosense Webster (Johnson & Johnson): Market-leading electrophysiology division of J&J, dominant in 3D mapping (CARTO) and RF ablation catheters. It is comparable as the incumbent whose installed capital equipment ecosystem defines the AF ablation workflow in which esolution is used.
• Medtronic: Global leader in cardiac rhythm and ablation, including cryoballoon (Arctic Front) and pulsed field ablation systems. Comparable as the dominant EP incumbent whose ablation modalities set the workflow esolution must integrate with.
• Abbott: Major EP player through its cardiac arrhythmia portfolio, including the EnSite mapping system and TactiCath ablation catheters. Comparable as a broad incumbent EP ecosystem that defines procedure workflow for any AF ablation accessory.
• Boston Scientific: EP and cardiac surgery portfolio including the Rhythmia mapping system and cryo/RF ablation tools. Comparable as a broad incumbent whose AF ablation franchise competes for the same hospital accounts as S4 Medical.

Direct peers

• AtriCure: Specializes in atrial fibrillation surgical and catheter ablation, including the Isolator Synergy clamp and cryoICE probes. Comparable as a focused AF-ablation pure-play whose customer base (EP and cardiac surgery programs) overlaps directly with S4 Medical's target accounts.

Emerging players

• Kardium: Developer of the Globe Pulsed Field Ablation system for AF, an emerging modality positioned as potentially safer for the esophagus. Comparable as an emerging EP ablation company whose technology trajectory influences demand for separate esophageal protection accessories.
• Adagio Medical: Developer of ultra-low temperature cryoablation for AF and VT, positioned as a next-generation single-shot ablation modality. Comparable as an emerging EP ablation competitor whose modality choice may shape the procedural risk profile esolution addresses.
• Affera (Medtronic): Acquired by Medtronic for its Prism-1 mapping and pulsed field ablation system. Comparable as an emerging PFA entrant whose modality adoption shifts the competitive backdrop for esophageal protection devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/S4med
• LinkedInlinkedin.com/company/s4medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S4 Medical